[go: up one dir, main page]

WO2004029280A3 - Dosage biologique anti-hla et procedes - Google Patents

Dosage biologique anti-hla et procedes Download PDF

Info

Publication number
WO2004029280A3
WO2004029280A3 PCT/US2003/030096 US0330096W WO2004029280A3 WO 2004029280 A3 WO2004029280 A3 WO 2004029280A3 US 0330096 W US0330096 W US 0330096W WO 2004029280 A3 WO2004029280 A3 WO 2004029280A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hla
hla assay
assay
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/030096
Other languages
English (en)
Other versions
WO2004029280A2 (fr
Inventor
Rico Buchli
William H Hildebrand
Christopher Giberson
Rod Vangundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/337,161 external-priority patent/US20060276629A9/en
Priority claimed from PCT/US2003/000243 external-priority patent/WO2003057852A2/fr
Application filed by Individual filed Critical Individual
Priority to CA002539622A priority Critical patent/CA2539622A1/fr
Priority to AU2003270876A priority patent/AU2003270876A1/en
Publication of WO2004029280A2 publication Critical patent/WO2004029280A2/fr
Publication of WO2004029280A3 publication Critical patent/WO2004029280A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés de dosage biologique anti-HLA faisant intervenir des molécules HLA solubles individuelles, fonctionnellement actives, isolées et purifiées essentiellement sans contact avec d'autres protéines.
PCT/US2003/030096 2002-09-24 2003-09-24 Dosage biologique anti-hla et procedes Ceased WO2004029280A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002539622A CA2539622A1 (fr) 2002-09-24 2003-09-24 Dosage biologique anti-hla et procedes
AU2003270876A AU2003270876A1 (en) 2002-09-24 2003-09-24 Anti-hla assay and methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41384202P 2002-09-24 2002-09-24
US60/413,842 2002-09-24
US10/337,161 US20060276629A9 (en) 1999-12-17 2003-01-02 Purification and characterization of soluble human HLA proteins
PCT/US2003/000243 WO2003057852A2 (fr) 2001-12-18 2003-01-02 Purification et caracterisation de proteines hla
US10/337,161 2003-01-02
USPCT/US03/00243 2003-01-02

Publications (2)

Publication Number Publication Date
WO2004029280A2 WO2004029280A2 (fr) 2004-04-08
WO2004029280A3 true WO2004029280A3 (fr) 2004-07-15

Family

ID=32684708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030096 Ceased WO2004029280A2 (fr) 2002-09-24 2003-09-24 Dosage biologique anti-hla et procedes

Country Status (2)

Country Link
AU (1) AU2003270876A1 (fr)
WO (1) WO2004029280A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5779599B2 (ja) 2010-02-17 2015-09-16 ワン ラムダ， インコーポレイテッド 天然ヒト白血球抗原に対する抗体を検出するための組成物および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255073B1 (en) * 1995-03-08 2001-07-03 The Scripps Research Institute Antigen presenting system and methods for activation of T-cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255073B1 (en) * 1995-03-08 2001-07-03 The Scripps Research Institute Antigen presenting system and methods for activation of T-cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRILLIMAN K.R. ET AL.: "HLA-B15 peptide ligands are preferentially anchored at their C termini", JOURNAL OF IMMUNOLOGY, vol. 162, 1999, pages 7277 - 7284, XP002966691 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use

Also Published As

Publication number Publication date
WO2004029280A2 (fr) 2004-04-08
AU2003270876A1 (en) 2004-04-19
AU2003270876A8 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
WO2005047314A3 (fr) Peptides supportes et peptides fixant a fgf-5
WO2004029207A3 (fr) Variants fc optimises et methodes destinees a leur generation
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
WO2001064920A3 (fr) Expressions hybrides de proteines de neisseria
WO2004048399A3 (fr) Peptides de liaison cutanee ou capillaire
WO2003056336A3 (fr) Matrice de liaison a structure fonctionnelle amelioree pour biomolecules
WO2004006667A3 (fr) Procedes de regeneration et de transformation du coton
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
TW200612945A (en) Aerosol suspension formulations containing TG 227 ea as propellant
GB0100513D0 (en) Process
WO2002026968A3 (fr) Acides nucleiques iap antisens et utilisations associees
WO2005047494A3 (fr) Cellules souches convenant a la transplantation: preparation et compositions pharmaceutiques contenant ces cellules
WO2004087735A3 (fr) Anticorps proteolytiques et covalents
WO2003074546A3 (fr) Peptide de liaison a la streptavidine
WO2005000888A3 (fr) Nouveaux promoteurs de l'actine beta et de la rps21, et leurs utilisations
WO2003099192A3 (fr) Alcanols bi-aromatiques
WO2001098367A3 (fr) Peptides neuroactifs servant a traiter l'hypoxie et des etats apparentes
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
EP1262556A3 (fr) Peptides antimicrobiens et leur identification et utilisation
WO2001036453A3 (fr) Derives peptidiques de ny-eso-1 et leurs applications
HK1046925A1 (zh) Mage-a12抗原肽及其用途
AU7525398A (en) Inhibitors for urokinase receptor
WO2004029280A3 (fr) Dosage biologique anti-hla et procedes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2539622

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP